András S.
- Country
- Hungary
- Department
- Ophtalmology
Research Overview
- A Randomized, Double-masked Study Comparing the Efficacy and Safety of AVT29 Versus High-Dose Aflibercept in Participants with Diabetic Macular Edema
- A Phase 3 Randomized Study Comparing the Efficacy of Vorolanib to Aflibercept in Participants with Diabetic Macular Edema
- Dose-ranging study of FWY003 in geographic atrophy secondary to age-related macular degeneration: randomized, double-masked, placebo-controlled trial in adults
Data & Insights
Has run more than one trial at 198 of 343 partner sites.
Specializations
Retinal Disorders
Specializes in treating various forms of macular degeneration and related conditions, including geographic atrophy and neovascular AMD. Investigates innovative therapeutic approaches for diabetic macular edema and diabetic retinopathy.
- Age-related Macular Degeneration
- Diabetic Eye Complications
- Retinal Vein Occlusion
Focuses on developing treatment strategies for retinal vascular diseases and vision preservation.
Inflammatory Eye Conditions
Concentrates on treating thyroid eye disease through various therapeutic approaches. Investigates treatments for non-infectious uveitis, including intermediate, posterior, and panuveitis forms.
- Thyroid Eye Disease Management
- Non-infectious Uveitis
- Inflammatory Eye Disorders
Explores novel biological therapies and immunomodulatory treatments for inflammatory eye conditions.
Vision Disorders
Addresses various vision conditions including myopia in pediatric patients and acquired blepharoptosis. Studies innovative treatments for vision improvement and maintenance.
- Pediatric Myopia Control
- Eyelid Disorders
- Visual Acuity Enhancement
Implements advanced therapeutic approaches for vision correction and enhancement.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.